Blood cell therapy最新文献

{"title":"A Discount on the Cost of Cancer: India's Homegrown CAR-T Cell Therapy.","authors":"Muhammad Abdul Rehman, Hamza Arshad","doi":"10.31547/bct-2024-008","DOIUrl":"10.31547/bct-2024-008","url":null,"abstract":"<p><p>Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment of blood cancer. By improving survival outcomes for patients with B-cell malignancies, which hitherto have been unparalleled by conventional chemotherapy, CAR-T therapy is a beacon of hope for many patients with cancer. However, harvesting, modifying, and reintroducing T cells is costly, which means that not every patient with cancer who needs CAR-T therapy has the financial capacity to receive it. This blatant economic disparity, combined with geographical limitations, for several lower-middle-income countries that do not manufacture CAR-T therapy, has been a problem that has widened the socioeconomic gap between patients with cancer. This was the case until India recently manufactured its own CAR-T therapy. As a lower-middle-income country with a massive burden of cancer, India's NexCAR19 was a pivotal point in South Asian cancer history. From benefiting local patients with cancer to collaborations with neighboring countries, to prompting the manufacture of more CAR-T products, NexCAR19 has facilitated the fight against blood cancers in South Asia.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 4","pages":"121-123"},"PeriodicalIF":0.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis in a patient with acute lymphoblastic leukemia.","authors":"Takashi Koike, Daisuke Toyama, Mayuko Shibata, Kohei Otsuka, Yumiko Sugishita, Ryota Kaneko, Naoko Kawabata, Sachio Fujita, Kosuke Akiyama, Shohei Yamamoto","doi":"10.31547/bct-2024-010","DOIUrl":"10.31547/bct-2024-010","url":null,"abstract":"<p><p>Immune effector cell-associated neurotoxicity syndrome usually occurs within the first four weeks of chimeric antigen receptor (CAR)-T cell therapy. In addition, prolonged cytopenia is a long-term adverse effect following the use of CAR T-cell therapies. Here, we present a case of prolonged severe cytopenia followed by fatal CAR T-cell-mediated encephalitis. A 22-year-old male patient was referred to our hospital for a second relapse of B-cell precursor acute lymphoblastic leukemia (ALL), which was diagnosed 22 months after hematopoietic stem cell transplantation from an unrelated donor. CAR T-cells (tisagenlecleucel) were infused during the third cycle of complete remission after chemotherapy. The patient developed grade 2 cytokine release syndrome requiring a single dose of tocilizumab. Cytopenia was profound from day 30 onward, but no other serious complications were observed. On day 50, the patient developed sensory impairment, disturbing behavior, and confusion. Brain magnetic resonance imaging (MRI) scan and cerebrospinal fluid (CSF) analysis revealed no pathological findings. Severe neutropenia persisted despite G-CSF treatment, and the patient's neurological symptoms rapidly progressed from day 65. Brain MRI revealed hydrocephalus. The CSF showed elevated xanthochromia, mononuclear cell counts, and protein levels. A therapeutic attempt with prednisolone for encephalitis was ineffective, and the patient died on day 77 owing to neurological toxicity. Late-onset CAR T-cell-mediated encephalitis was suspected, although the CSF was not assessed for CAR T-cells. In addition, the patient developed prolonged and severe cytopenia. To the best of our knowledge, this is the first report of prolonged severe cytopenia followed by late-onset CAR T-cell-mediated encephalitis. These unexpected long-term adverse effects may occur and should also be considered.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 4","pages":"118-120"},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum 5-S-cysteinyldopa as a predictive biomarker for stem cell transplantation-related complications in children and young adults.","authors":"Yukayo Terashita, Akihiro Iguchi, Minako Sugiyama, Yuko Cho, Houman Goudarzi, Isao Yokota, Atsushi Manabe","doi":"10.31547/bct-2024-001","DOIUrl":"10.31547/bct-2024-001","url":null,"abstract":"<p><p>Diffuse hyperpigmentation is common in patients who undergo chemotherapy or stem cell transplantation (SCT). However, only a few studies have reported the relation between skin reactions and SCT-related complications. Serum 5-S-cysteinyldopa (5SCD), a pheomelanin precursor, is elevated in individuals with hyperpigmentation. Here, we serially examined 5SCD levels during SCT to determine their association with SCT-related complications. We prospectively analyzed serum 5SCD levels in 41 patients (median age: 7.9 years; range: 0-22 years) who underwent SCT (allogeneic in 34 patients and autologous in 7 patients). The serum level of 5SCD increased on day 0, remained high on day 5, and gradually decreased to baseline levels on day 40 after SCT. An increase in 5SCD levels on day 0 was associated with the presence of viral reactivation (odds ratio [OR]: 3.32; 95% confidence interval [CI] 1.07-10.21, <i>p</i> = 0.002) while an increase in 5SCD levels on day 5 was associated with pre-engraftment syndrome (OR: 2.18; 95% CI 1.11-4.26, <i>p</i> = 0.007). In patients who underwent allogeneic SCT, the difference between the baseline level of 5SCD before SCT and the highest level after SCT was associated with acute graft-versus-host disease (GVHD) (OR for a 10 nmol/L increase in biomarker levels: 1.90; 95% CI 1.04-3.45, <i>p</i> = 0.015) and acute cutaneous GVHD (OR for a 10 nmol/L increase in biomarker levels: 2.34; 95%CI 1.11-4.52, <i>p</i> = 0.005). The conditioning regimen was not associated with serum 5SCD levels. Therefore, this study demonstrated the potential of 5SCD as a predictive biomarker for SCT-related complications, such as viral reactivation, pre-engraftment syndrome, and acute GVHD.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 4","pages":"111-117"},"PeriodicalIF":0.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A likely case of chronic graft-versus-host disease polymyositis affecting respiratory and truncal muscles - a comprehensive diagnostic approach.","authors":"Jing Yuan Tan, Jeffrey Kim Siang Quek, Ming Lee, Lai Peng Chan, William Ying Khee Hwang, Francesca Wei Inng Lim, Aloysius Yew Leng Ho, Yeh Ching Linn, Yeow Tee Goh, Hein Than","doi":"10.31547/bct-2023-040","DOIUrl":"10.31547/bct-2023-040","url":null,"abstract":"<p><strong>Background: </strong>Muscle involvement, termed polymyositis, is an uncommon manifestation of graft-versus-host disease (GvHD) in which the upper and lower limbs are commonly affected. However, respiratory failure due to diaphragmatic weakness has rarely been reported. Diagnosis is usually based on a combination of elevated muscle enzyme levels in the blood, neurophysiological studies, and muscle biopsies.</p><p><strong>Case report: </strong>A 23-year-old man who presented with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in myeloid blast crisis, underwent HLA-matched sibling (sister) hematopoietic stem cell transplantation. Six months post-transplant, he experienced bilateral arm pain and weakness, with an inability to raise his limbs against gravity. He was also unable to sit erect, and was dyspneic and hypoxic, thus requiring oxygen supplementation. Serum muscle enzyme levels were found to be markedly elevated. Magnetic resonance imaging showed a patchy hyperintense T2-weighted signal and enhancement in the muscle groups of the limbs, as well as in the psoas and erector spinae muscles. The electromyogram results were consistent with those of inflammatory myopathy. Muscle biopsy revealed extensive necrotizing myositis with extensive lymphocyte infiltration throughout the muscle fascicle. Additionally, fluorescence in situ hybridization (FISH) analysis demonstrated that 30% of the nuclei scored were in the muscle fibers of recipient XY origin, and 70% were in T-lymphocytes of donor XX origin. GvHD polymyositis was diagnosed, and the patient responded well to corticosteroids and extracorporeal photopheresis.</p><p><strong>Conclusion: </strong>GvHD polymyositis can affect various muscle groups and results in various clinical presentations. In our case, truncal involvement resulting in an inability to sit erect was a unique presentation. Prompt diagnosis is important, and we have highlighted a comprehensive multimodal approach, including the potential use of FISH analysis, to aid in diagnosis.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 4","pages":"106-110"},"PeriodicalIF":0.0,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A role for diet and gut microbiota metabolites in autologous hematopoietic cell transplant recipients.","authors":"Shaweta Kaundal, Amol N Patil, Lekshmon Ks, Vishal Sharma, Amit Arora, Charanpreet Singh, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra, Deepesh P Lad","doi":"10.31547/bct-2024-007","DOIUrl":"10.31547/bct-2024-007","url":null,"abstract":"<p><strong>Introduction: </strong>The gut microbiome has an established role in allogeneic hematopoietic cell transplantation (allo-HCT), but not in an auto-HCT setting. We have hypothesized that fecal short-chain fatty acids (SCFA) and urinary 3-indoxyl sulfate (3-IS), which are metabolites derived from the action of the gut microbiome on dietary fiber, play a role in auto-HCT outcomes.</p><p><strong>Methods: </strong>This was a single-center prospective study involving auto-HCT recipients. Baseline patient and disease details, diet diaries, and antibiotic exposure were recorded in consenting patients. Serial (pre-HCT, week two, and week four post-HCT) SCFA and urine 3-IS levels were measured using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). HCT outcomes were correlated with these metabolites.</p><p><strong>Results: </strong>Thirty patients (myeloma, n=13; lymphoma, n=17) were analyzed. The levels of urinary 3-IS, fecal acetate, propionate, and butyrate were found to be decreased at week two and were recovered by week four post-HCT. Those with low median nadir fecal butyrate levels at week two also had significantly lower pre-HCT and week four butyrate levels. Recipients with low butyrate levels had more grade ≥2 mucositis (80% vs. 33%, <i>p</i>=0.01) and low fiber intake (10.4 g vs. 13.6 g, <i>p</i>=0.04). They also had more carbapenem exposure (93% vs. 47%, <i>p</i>=0.005) and prolonged antibiotics (11 days vs. 8 days, <i>p</i>=0.008). There were no differences in the time to neutrophil or platelet engraftment, mortality, or disease response.</p><p><strong>Conclusion: </strong>Low pre-HCT fecal butyrate levels tend to persist post-HCT and they are associated with mucositis, dietary fiber intake, and antibiotic exposure. The gut microbiome and its modulation may play a role in auto-HCT settings.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 4","pages":"101-105"},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142803650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for Fanconi anemia with/without anti-thymocyte globulin.","authors":"Ramya Uppuluri, Venkateswaran Vellaichamy Swaminathan, Kavitha Ganesan, Suresh Duraisamy, Anupama Nair, Vijayshree Muthukumar, Anuraag Reddy Nalla, Logesh Balakrishnan, Revathi Raj","doi":"10.31547/bct-2024-006","DOIUrl":"https://doi.org/10.31547/bct-2024-006","url":null,"abstract":"<p><strong>Background: </strong>We present comparative data of children with Fanconi anemia undergoing haploidentical hematopoietic stem cell transplantation (HSCT) with or without the addition of rabbit anti-thymocyte globulin (r-ATG) to the conditioning regimen.</p><p><strong>Patients and methods: </strong>This retrospective study included children with Fanconi anemia aged up to 18 years who underwent haploidentical HSCT between January 2015 and December 2022. The children were included in two cohorts in this study. Cohort 1 included children who received conditioning with fludarabine/cyclophosphamide/single fraction of 2 Gy TBI. The children in cohort 2 received the same conditioning along with r-ATG. Post-transplant cyclophosphamide was administered at a dose of 25 mg/kg on day3 and day4 in both cohorts.</p><p><strong>Results: </strong>A total of 35 children were included in the study, 25 in cohort 1 and 10 in cohort 2. Neutrophil engraftment was documented around day 14-16 post infusion in 21 children (84%) in cohort 1 and in 8 children (80%) in cohort 2. There was a significant difference in the incidence of the severity of graft versus host disease (GVHD) between the two cohorts (<i>p</i> = 0.003). In cohort 1, acute GVHD was documented in 17 children (68%), with grade 1/2 skin GVHD in 10 children, and grade 3/4 skin and gut GVHD in 7 children. Grade 4 gut GVHD was the cause of death in three children in cohort 1. In cohort 2, acute GVHD was documented in one child (10%) who had grade 4 skin and gut GVHD and succumbed to the above. Chronic GVHD was noted in nine (36%) children in cohort 1, and in one child (10%) in cohort 2. Cytomegalovirus reactivation was documented in 11 children (44%) in cohort 1 and three children (30%) in cohort 2. Overall survival was found to be 16/25 (64%) in cohort 1, with a median follow-up of 49 months, and 7/10 (70%) in cohort 2, with a median follow-up of 12 months.</p><p><strong>Conclusion: </strong>Serotherapy with r-ATG significantly reduced the incidence of GVHD from 68% to 10% in children with Fanconi anemia, with an increase in overall survival from 64% to 70%, although it did not affect graft failure. Further studies should focus on decreasing graft failure rates with early HSCT before multiple transfusions.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 3","pages":"95-100"},"PeriodicalIF":0.0,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized controlled trial of pre-transplant zoledronate versus observation for prevention of bone loss in allogeneic hematopoietic cell transplantation.","authors":"Niranjan Khaire, Urmimala Bhattacharjee, Arjun Dinesan, Anindita Sinha, Sanjay Bhadada, Andrew Pardeep, Prashant Chhabra, Ritika Sharma, Renaissa De, Shaweta Kaundal, Kripa Shanker Kasudhan, Lekshmon Ks, Charanpreet Singh, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Amol Patil, Pankaj Malhotra, Deepesh Lad","doi":"10.31547/bct-2024-003","DOIUrl":"https://doi.org/10.31547/bct-2024-003","url":null,"abstract":"<p><strong>Background: </strong>Approximately half of allogeneic hematopoietic cell transplantation (HCT) recipients experience significant bone loss in the early post-HCT period. Only recently have international guidelines started recommending early screening. However, the guidance for intervention remains conservative. In this study, we sought to evaluate the efficacy of pre-transplant prophylactic zoledronate in preventing early bone loss in allogeneic HCT recipients.</p><p><strong>Methods: </strong>This was an open-label, investigator-initiated, phase 2 randomized controlled trial (RCT) of prophylactic zoledronate versus observation to prevent bone loss in allogeneic HCT recipients. Recipients aged ≥ 18 years of age were included after informed consent and randomized to prophylactic zoledronate 4 mg pre-HCT or observation in a 1:1 ratio. The primary outcome of the study was bone mineral density (BMD) loss at the femoral neck (FN), total hip (TH), and lumbar spine (LS), as assessed using dual-energy X-ray absorptiometry (DXA) on day+100 post-HCT. The secondary outcomes included BMD loss on day+365 and Z scores on day+100 and day+365 at the FN, TH, and LS sites.</p><p><strong>Results: </strong>The trial was terminated because the interim analysis showed a significant benefit in the intervention arm, with 50% planned recruitment. A total of 40 patients were randomized to the zoledronate and control arms. Both arms were matched for age, sex, diagnosis, pre-HCT steroid exposure, body mass index, human leukocyte antigen (HLA) match, and conditioning intensity. The grade 2-4 acute graft versus host disease (GVHD) incidences were comparable. The primary endpoint of BMD loss at FN and TH at day+100 was significant (5.62% vs. -6.78%, <i>p</i> = 0.009, -1.59 vs. -3.98, <i>p</i> = 0.016, respectively). There was no difference in the secondary endpoint of BMD loss on day+365 compared to that on day+100 or baseline at any BMD site. There was no difference in the Z-scores at any site on day+100 or day+365.</p><p><strong>Conclusions: </strong>Prophylactic zoledronate prevented early bone loss on day+100. The indicated preemptive zoledronate beyond day+100 in recipients prevented further bone loss. Patients receiving prophylactic zoledronate may benefit from a supplementary dose of the indicated preemptive zoledronate.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 3","pages":"87-94"},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive Estimation of Microvasculopathy & Endothelial Dysfunction in Stem Cell Transplant Recipients and its Relationship with GVHD.","authors":"Sayan Sinha Roy, Raghuraman Sondararajan, Arun Sharma, Manphool Singhal, Shefali Sharma, Pankaj Malhotra, Charanpreet Singh, Arihant Jain, Alka Khadwal, Gaurav Prakash","doi":"10.31547/bct-2023-041","DOIUrl":"https://doi.org/10.31547/bct-2023-041","url":null,"abstract":"<p><strong>Introduction: </strong>Microvasculopathy and endothelial dysfunction play important roles in the development of post-transplant complications, including graft-versus-host disease (GVHD). We assessed structural microvasculopathy by employing nailfold video capillaroscopy (NFVC) and endothelial dysfunction via flow-mediated dilatation (FMD) of the brachial artery in recipients of hematopoietic stem cell transplantation.</p><p><strong>Patients and methods: </strong>Recipients of stem cell transplantation were included in this study post day+100 and divided into two cohorts. The first cohort consisted of 35 recipients of allogeneic hematopoietic stem cell transplantation (HCT) and the second cohort was comprised of 31 recipients of autologous HCT. A third cohort included 35 healthy individuals. NFVC was conducted on the second to fifth fingers of both hands using an Optilia video capillaroscope at 200× magnification, and the images were analyzed according to the European Alliance of Associations for Rheumatology (EULAR) criteria. The following parameters were used to measure vasculopathy: (a) median capillary density, derived from the capillary density of eight fingers, (b) median capillary diameter, derived from maximum capillary apical diameters of eight fingers, and (c) significant neoangiogenesis (neoangiogenesis present in ≥2 fingers). FMD of the right brachial artery was observed by high-resolution ultrasonography using the principle of post-occlusive reactive hyperemia, and video images were analyzed using edge-detecting software.</p><p><strong>Results: </strong>The median capillary diameter was significantly higher in the allo-HCT cohort (20.56±5.17 micrometer) compared to the auto-HCT cohort (16.19±3.31 micrometer; <i>p</i><0.001) and healthy controls (14.66±2.61 micrometer; <i>p</i><0.001). The median capillary density was significantly lower in the allo-HCT cohort (median: 6 capillaries/mm, range: 5-9 capillaries/mm) compared to the auto-HCT cohort (median: 8.5 capillaries, range: 5-12 capillaries/mm; <i>p</i><0.001) and healthy controls (median: 8 capillaries/mm, range: 7-10.5 capillaries/mm; <i>p</i><0.001). The allo-HCT cohort had a higher proportion of patients with significant neoangiogenesis (86%) than the auto-HCT cohort (10%) and healthy controls (9%). The presence of significant neoangiogenesis was more frequent in the subgroup of patients with a history of GVHD (93%) compared to the subgroup of patients without any history of GVHD (57%; <i>p</i>=0.044). No significant differences in NFVC parameters or FMD were observed between recipients of myeloablative and reduced-intensity conditioning regimens. There was no significant difference in NFVC parameters between the auto-HCT cohort and healthy controls. There was no significant difference in FMD among the three cohorts; however, a higher proportion of patients in the allo-HCT cohort (28%) had lower FMD than those in the auto-HCT cohort (3%) and healthy controls (6%), sug","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 3","pages":"79-86"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.","authors":"E Tamellini, M Sorio, A Andreini, C Tecchio, G Nadali, A Bernardelli, I Ferrarini, L Crosera, A Vatteroni, C Simio, F Benedetti, M Krampera, I Tanasi","doi":"10.31547/bct-2024-005","DOIUrl":"https://doi.org/10.31547/bct-2024-005","url":null,"abstract":"<p><p>Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 3","pages":"75-78"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recovery of physical function, muscle mass, and quality of life in patients undergoing allogeneic hematopoietic stem cell transplantation.","authors":"Takahiro Takekiyo, Atae Utsunomiya, Souichiro Nara, Norihisa Nakashima, Toshiyuki Okamura, Masahito Tokunaga, Takayoshi Miyazono, Nobuaki Nakano, Yoshikiyo Ito, Koichiro Dozono","doi":"10.31547/bct-2023-034","DOIUrl":"https://doi.org/10.31547/bct-2023-034","url":null,"abstract":"<p><p>This study aimed to investigate the recovery of physical function, muscle mass, and quality of life (QOL) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients 1 year after the procedure. A total of 71 patients who underwent allo-HSCT at our institution between February 2010 and June 2020, for whom a physical therapy assessment could be performed before allo-HSCT, at discharge, and 1 year after the procedure, were included. Exercise therapy during hospitalization was provided individually by a physical therapist, and exercise was self-administered after discharge. One year after allo-HSCT, handgrip strength and results of the 6-minute walk test recovered to pre-HSCT levels. However, muscle mass 1 year after allo-HSCT did not reach the pre-HSCT level. All subscales of QOL, 1 year after allo-HSCT, recovered to pre-HSCT levels, but only two of the eight subscales recovered to the national standard of 50. Multivariate analysis revealed factors associated with the recovery of physical function, muscle mass, and QOL, hemoglobin levels and albumin levels, especially among men. In contrast, factors that negatively affected recovery were age, acute graft-versus-host disease, and pre-HSCT intensity conditioning. The results suggest a potential recovery in handgrip strength, endurance, and QOL 1 year after allo-HSCT.</p>","PeriodicalId":72423,"journal":{"name":"Blood cell therapy","volume":"7 3","pages":"64-74"},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11384126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}